Novo Nordisk: The 7.2mg semaglutide Phase 3 clinical trial achieved its primary endpoint, with a 20.7% weight loss over 72 weeks

According to Jinshi Data on January 18, local time on January 17, Novo Nordisk announced the main results of the Phase 3 clinical trial STEP UP. In the STEP UP obesity trial, a weekly subcutaneous injection of 7.2mg semaglutide resulted in a weight loss of 20.7% at 72 weeks, with a weight loss of 18.7% regardless of treatment adherence. The trial achieved its primary endpoint, showing statistically significant and superior weight loss compared to placebo at week 72 with 7.2mg semaglutide